Thursday, April 2, 2020. Roszkowski-Sliz is the Director and Head of Clinical of the National Tuberculosis and Lung Diseases Research Institute in Poland; National Consultant for Lung Diseases, Ministry of Health; Chairman of Scientific Council of Ministry of Health; and Chairman of the Scientific Council of the National Center Institute of Oncology Poland. Provides Update On The Timing Of Filing Of Third Quarter Results - GlobeNewswire , 5:15 PM EDT. About Who we are We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. By doing so at the site of cancerous tissues in the body, the Company believes DOS47 can modify the micro environmental conditions of cancerous cells in a manner that leads to apoptosis (programmed cell death).DOS47 - A patented oncology platform technology that offers a new and potentially revolutionary approach to the debilitation and destruction of cancer cellsDOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumour.
We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.Public company CFO with broad industry experience including senior positions with Unilever and Huhtamaki OyOver 30 years of experience in financial and industrial sector. No Headlines Available. (ClinicalTrials.gov Identifier: NCT03891173)LDOS006 is a new Phase I/II study in the U.S. of L-DOS47 in combination with doxorubicin for the treatment of metastatic pancreatic cancer.

DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells. Blue Flamingo 7, 2011 at 7:54 a.m. ET. Dr. Gillies is an expert in tumor acidity and has published extensively in this area of research.© 2020 Helix BioPharma Corp. All Rights Reserved. Helix BioPharma Corp. News Headlines for Helix BioPharma Corp. Thursday, June 11, 2020. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. L-DOS47 is currently being evaluated for non-small cell lung cancer (NSCLC) and pancreatic cancer. Recent News.

Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company, which develops products for the treatment and prevention of cancer. Helix continues to explore opportunities to expand upon its product pipeline with new DOS47 based therapeuticsDOS47 candidates are produced by conjugating urease with a targeting antibody or antibody fragment that can specifically direct the urease to the surface of a cancer cell. Once docked to the cell, the urease produces ammonia enzymatically through the conversion of urea found throughout the body. L-DOS47 is  an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills. Dr. Roszkowski-Sliz is an expert in the treatment of lung diseases.Dr. V-DOS47 targets the vascular endothelial growth factor 2 receptor (VEGFR2). These conjugates of antibodies to urease are called DOS47 candidates. L-DOS47 is the Company’s first targeted therapeutic immunoconjugate under development based on the DOS47 technology.

The local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.Helix believes that DOS47 may have applications both as a monotherapy and in certain combined adjunct chemotherapy regimensL-DOS47 is the Company’s first targeted therapeutic immunoconjugate under development based on the DOS47 technology. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020 - GlobeNewswire , 7:30 AM EDT .

Robert Gillies holds the Martin Silbiger Endowed Chair and is Chair of the Department of Cancer Physiology and Vice-Chair (Research) of the Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute; and Professor Emeritus, Departments of Radiology and Biomedical Engineering, College of Medicine University of Arizona. A second DOS47 candidate, known as V-DOS47, targets the vascular epithelial growth factor receptor 2 and is at preclinical development. Helix believes that DOS47 may have applications both as a monotherapy and in certain combined adjunct chemotherapy regimens. Former General Director of the Supervisory Board of ORLEN Lietuva.Dr. (ClinicalTrials.gov Identifier: NCT02340208)LDOS003 is an open-label Phase IIb clinical trial of L-DOS47 in combination with vinorelbine/cisplatin in NSCLC patients with metastatic lung adenocarcinoma.
L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. (ClinicalTrials.gov Identifier: NCT04203641)© 2020 Helix BioPharma Corp. All Rights Reserved. Canada hot stocks to watch: Teck, TMX, Helix Jun.

Pipeline DOS47 Drug Candidates Our most advanced Tumor Defence Breaker L-DOS47 is currently in clinical trials for the treatment of small cell lung cancer (NSCLC) and pancreatic cancer. It focuses on the medicines … The L-DOS47 drug molecule includes a highly specialized camelid-derived single domain antibody and is currently under clinical study for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer.V-DOS47 is the second immuno-oncology drug candidate derived from the Company’s DOS47 technology platform.